First-in-human intracisternal dosing of RGX-111 in severe MPS I is well tolerated and generates sustained neurodevelopment without HSCTRaymond Wang, Laura Rosa Pisani, Shih‐hsin Kan et al.|Molecular Therapy|2026Cited by 0